RESUMEN
Cooperating gene mutations are typically required to transform normal cells enabling growth in soft agar or in immunodeficient mice. For example, mutations in Kras and transformation-related protein 53 (Trp53) are known to transform a variety of mesenchymal and epithelial cells in vitro and in vivo. Identifying other genes that can cooperate with oncogenic Kras and substitute for Trp53 mutation has the potential to lead to new insights into mechanisms of carcinogenesis. Here, we applied a genome-wide CRISPR/Cas9 knockout screen in KrasG12D immortalized mouse embryonic fibroblasts (MEFs) to search for genes that when mutated cooperate with oncogenic Kras to induce transformation. We also tested if mutation of the identified candidate genes could cooperate with KrasG12D to generate primary sarcomas in mice. In addition to identifying the well-known tumor suppressor cyclin dependent kinase inhibitor 2A (Cdkn2a), whose alternative reading frame product p19 activates Trp53, we also identified other putative tumor suppressors, such as F-box/WD repeat-containing protein 7 (Fbxw7) and solute carrier family 9 member 3 (Slc9a3). Remarkably, the TCGA database indicates that both FBXW7 and SLC9A3 are commonly co-mutated with KRAS in human cancers. However, we found that only mutation of Trp53 or Cdkn2a, but not Fbxw7 or Slc9a3 can cooperate with KrasG12D to generate primary sarcomas in mice. These results show that mutations in oncogenic Kras and either Fbxw7 or Slc9a3 are sufficient for transformation in vitro, but not for in vivo sarcomagenesis.
Asunto(s)
Proliferación Celular , Transformación Celular Neoplásica/patología , Mutación , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas Proto-Oncogénicas p21(ras)/genética , Sarcoma Experimental/prevención & control , Animales , Sistemas CRISPR-Cas , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Células Cultivadas , Embrión de Mamíferos/citología , Embrión de Mamíferos/metabolismo , Fibroblastos/citología , Fibroblastos/metabolismo , Regulación Neoplásica de la Expresión Génica , Ratones , Ratones Endogámicos C57BL , Ratones Desnudos , Proteínas de Neoplasias/genética , Sarcoma Experimental/genética , Sarcoma Experimental/patología , Transducción de SeñalRESUMEN
BACKGROUND: To develop a vaccine-based immunotherapy for sarcoma, we evaluated a mixture of heat shock proteins (mHSPs) as a vaccine for sarcoma treatment in a mouse model. Heat shock protein/peptides (HSP/Ps) are autoimmune factors that can induce both adaptive and innate immune responses; HSP/Ps isolated from tumors can induce antitumor immune activity when used as vaccines. METHODS: In this study, we evaluated the effects of mHSP/Ps on prophylactic antitumor immunity. We extracted mHSP/Ps, including HSP60, HSP70, GP96, and HSP110, from the mouse sarcoma cell lines S180 and MCA207 using chromatography. The immunity induced by mHSP/Ps was assessed using flow cytometry, ELISPOT, lactate dehydrogenase release, and enzyme-linked immunosorbent assay. RESULTS: Of S180 sarcoma-bearing mice immunized with mHSP/Ps isolated from S180 cells, 41.2% showed tumor regression and long-term survival, with a tumor growth inhibition rate of 82.3% at 30 days. Of MCA207 sarcoma-bearing mice immunized with mHSP/Ps isolated from MCA207 cells, 50% showed tumor regression and long-term survival with a tumor growth inhibition rate of 79.3%. All control mice died within 40 days. The proportions of natural killer cells, CD8+, and interferon-γ-secreting cells and tumor-specific cytotoxic T-lymphocyte activity were increased in the immunized group. CONCLUSIONS: Vaccination with a polyvalent mHSP/P cancer vaccine can induce an immunological response and a marked antitumor response to autologous tumors. This mHSP/P vaccine exerted greater antitumor effects than did HSP70, HSP60, or tumor lysates alone.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Proteínas de Choque Térmico/administración & dosificación , Sarcoma Experimental/prevención & control , Animales , Femenino , Inmunoterapia/métodos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Péptidos/administración & dosificación , VacunaciónRESUMEN
The chemopreventive and therapeutic efficacy of the cyclooxygenase (COX) inhibitor ibuprofen (IB) and of sulfasalazine (SASP), a drug that targets the antioxidant xc- system, were exploited in the experimental model of 3-methylcholantrene (3-MCA)-induced mouse sarcoma. The chemopreventive treatments gave unsatisfactory results because administration of IB one day after the 3-MCA injection only slightly delayed the tumor development, whereas SASP dispensed under the same conditions resulted in accelerated tumorigenesis. Similarly, the therapeutic treatment with either drug, administrated daily from the tumor detection, decreased the proliferation rate of tumor cells and increased the survival of treated mice only at a low extent. Remarkably, the combined chemopreventive treatment with IB and therapeutic treatment with SASP displayed a better efficacy, with strong delay of sarcoma growth, reduced tumor size and increased survival of treated mice. The two drugs target not only tumor cells but also tumor-associated macrophages that were dramatically decreased in the tumor infiltrate of mice subjected to the combined treatment. The synergistic effects of the association between a broad anti-inflammatory compound, such as IB, and a redox-directed drug, such as SASP, shed new light in the role of inflammation and of the redox response in chemical tumorigenesis and point to the combined chemopreventive plus therapeutic treatment with IB and SASP as a promising novel approach for antitumor therapy.
Asunto(s)
Sistema de Transporte de Aminoácidos y+/metabolismo , Anticarcinógenos/farmacología , Inhibidores de la Ciclooxigenasa/farmacología , Ibuprofeno/farmacología , Sarcoma Experimental/prevención & control , Sulfasalazina/farmacología , Adulto , Anciano , Sistema de Transporte de Aminoácidos y+/genética , Animales , Anticarcinógenos/uso terapéutico , Antioxidantes/metabolismo , Transformación Celular Neoplásica/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/uso terapéutico , Femenino , Expresión Génica/efectos de los fármacos , Humanos , Ibuprofeno/uso terapéutico , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Masculino , Metilcolantreno , Ratones , Ratones Endogámicos BALB C , Persona de Mediana Edad , Oxidación-Reducción , Especies Reactivas de Oxígeno/metabolismo , Sarcoma Experimental/inducido químicamente , Sarcoma Experimental/inmunología , Sarcoma Experimental/metabolismo , Sulfasalazina/uso terapéutico , Adulto JovenRESUMEN
Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel cyclic inhibitor of alpha-V integrins, has both anti-angiogenic and direct anti-tumor effects and is a possible alternative to TNF in ILP. In this study, rats bearing a hind limb soft tissue sarcoma underwent ILP using different combinations of melphalan, TNF and cilengitide in the perfusate. Further groups had intra-peritoneal (i.p.) injections of cilengitide or saline 2 hr before and 3 hr after ILP. A 77% response rate (RR) was seen in animals treated i.p. with cilengitide and perfused with melphalan plus cilengitide. The RR was 85% in animals treated i.p. with cilengitide and ILP using melphalan plus both TNF and cilengitide. Both RRs were significantly greater than those seen with melphalan or cilengitide alone. Histopathology showed that high RRs were accompanied by disruption of tumor vascular endothelium and tumor necrosis. Compared with ILP using melphalan alone, the addition of cilengitide resulted in a three to sevenfold increase in melphalan concentration in tumor but not in muscle in the perfused limb. Supportive in vitro studies indicate that cilengitide both inhibits tumor cell attachment and increases endothelial permeability. Since cilengitide has low toxicity, these data suggest the agent is a good alternative to TNF in the ILP setting.
Asunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Quimioterapia del Cáncer por Perfusión Regional , Recuperación del Miembro , Melfalán/uso terapéutico , Receptores de Vitronectina/antagonistas & inhibidores , Sarcoma Experimental/prevención & control , Venenos de Serpiente/uso terapéutico , Animales , Protocolos de Quimioterapia Combinada Antineoplásica , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Masculino , Ratas , Ratas Endogámicas BN , Sarcoma Experimental/metabolismoRESUMEN
An ideal anticancer strategy should target only the malignant cells but spare the normal ones. In this regard, we established a platform, consisting of an antigen-delivering vehicle and a protein vaccine, for developing an immunotherapeutic approach with the potential for eliminating various cancer types. Mesenchymal stem cells (MSCs) have been demonstrated capable of targeting tumors and integrating into the stroma. Moreover, we have developed a protein vaccine PE(ΔIII)-E7-KDEL3 which specifically recognized E7 antigen and elicited immunity against cervical cancer. Taking advantage of tumor-homing property of MSCs and PE(ΔIII)-E7-KDEL3, we used E6/E7-immortalized human MSCs (KP-hMSCs) as an E7 antigen-delivering vehicle to test if this protein vaccine could effectively eliminate non-E7-expressing tumor cells. Animals which received combined treatment of KP-hMSCs and PE(ΔIII)-E7-KDEL3 demonstrated a significant inhibition of tumor growth and lung-metastasis when compared to PE(ΔIII)-E7-KDEL3 only and KP-hMSCs only groups. The efficiency of tumor suppression correlated positively to the specific immune response induced by PE(ΔIII)-E7-KDEL3. In addition, this combined treatment inhibited tumor growth via inducing apoptosis. Our findings indicated that KP-hMSCs could be used as a tumor-targeting device and mediate antitumor effect of PE(ΔIII)-E7-KDEL3. We believe this strategy could serve as a platform for developing a universal vaccine for different cancer types.
Asunto(s)
Fibrosarcoma/prevención & control , Neoplasias Pulmonares/prevención & control , Células Madre Mesenquimatosas/inmunología , Proteínas E7 de Papillomavirus/inmunología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/uso terapéutico , Sarcoma Experimental/prevención & control , ADP Ribosa Transferasas/genética , ADP Ribosa Transferasas/inmunología , Animales , Apoptosis , Toxinas Bacterianas/genética , Toxinas Bacterianas/inmunología , Western Blotting , Linfocitos T CD8-positivos/inmunología , Ensayo de Inmunoadsorción Enzimática , Exotoxinas/genética , Exotoxinas/inmunología , Femenino , Fibrosarcoma/inmunología , Fibrosarcoma/patología , Genes MHC Clase I/inmunología , Humanos , Procesamiento de Imagen Asistido por Computador , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/secundario , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/metabolismo , Ratones , Persona de Mediana Edad , Proteínas Oncogénicas Virales/genética , Papillomaviridae/genética , Proteínas E7 de Papillomavirus/genética , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/patología , Fragmentos de Péptidos/metabolismo , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Sarcoma Experimental/inmunología , Sarcoma Experimental/patología , Linfocitos T Citotóxicos/inmunología , Factores de Virulencia/genética , Factores de Virulencia/inmunología , Exotoxina A de Pseudomonas aeruginosaRESUMEN
Both experimental and clinical data indicate that the sympathetic nervous system may affect the development of certain tumors. To test this, in the present study we combined in vivo and in vitro approaches to study the effect of the sympathetic nervous system on proliferation of BP6-TU2 fibrosarcoma cells. First, we investigated the effect of 6-hydroxydopamine-induced sympathectomy on tumor development and survival of tumor-bearing rats. One week after chemical sympathectomy, we injected the BP6-TU2 fibrosarcoma cells intraperitoneally into male Wistar rats. The sympathectomy significantly reduced the incidence of intraperitoneal tumors and resulted in significantly improved survival of tumor-bearing rats compared to those with intact sympathetic innervation. Using immunohistochemical methods, we found neuron-specific enolase immunopositive structures within fibrosarcoma tissue, indicating innervation of tumors. Finally, an in vitro study showed elevated proliferation of BP6-TU2 fibrosarcoma cells in response to adding norepinephrine to the culture medium. Our findings indicate that sympathetic nerves directly potentiate the proliferation of BP6-TU2 fibrosarcoma cells in rats.
Asunto(s)
Fibrosarcoma/prevención & control , Sarcoma Experimental/prevención & control , Simpatectomía Química , Sistema Nervioso Simpático/fisiología , Animales , Peso Corporal , Fibrosarcoma/patología , Humanos , Técnicas para Inmunoenzimas , Inyecciones Intraperitoneales , Masculino , Norepinefrina/farmacología , Oxidopamina , Ratas , Ratas Wistar , Sarcoma Experimental/patología , Tasa de Supervivencia , Simpaticolíticos , Simpatomiméticos/farmacología , Células Tumorales CultivadasRESUMEN
Immunotherapy using dendritic cells (DCs) has the potential to activate both T cells and NK cells. We previously demonstrated the long-lasting antitumor responses by NK cells following immunization with bone marrow-derived DCs. In the current study, we demonstrate that long-term antitumor NK responses require endogenous DCs and a subset of effector memory CD4(+) T (CD4(+) T(EM)) cells. One month after DC immunization, injection of a tumor into DC-immunized mice leads to an increase in the expression of CXCL10 by endogenous DCs, thus directing NK cells into the white pulp where the endogenous DCs bridged CD4(+) T(EM) cells and NK cells. In this interaction, CD4(+) T(EM) cells express CD40L, which matures the endogenous DCs, and produce cytokines, such as IL-2, which activates NK cells. These findings suggest that DC vaccination can sustain long-term innate NK cell immunity but requires the participation of the adaptive immune system.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Quimiocina CXCL10/inmunología , Células Dendríticas/inmunología , Células Asesinas Naturales/inmunología , Sarcoma Experimental/inmunología , Subgrupos de Linfocitos T/inmunología , Inmunidad Adaptativa , Animales , Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/metabolismo , Ligando de CD40/análisis , Vacunas contra el Cáncer/inmunología , Línea Celular Tumoral , Células Cultivadas , Quimiocina CXCL10/biosíntesis , Quimiocina CXCL10/genética , Citocinas/biosíntesis , Citocinas/inmunología , Células Dendríticas/citología , Células Dendríticas/metabolismo , Memoria Inmunológica , Interleucina-2/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Reacción en Cadena de la Polimerasa , Sarcoma Experimental/prevención & control , Transducción de SeñalRESUMEN
The interaction between cancer vaccine adjuvants and myeloid-derived suppressor cells (MDSCs) is currently poorly understood. Very small size proteoliposomes (VSSP) are a nanoparticulated adjuvant under investigation in clinical trials in patients with renal carcinoma, breast cancer, prostate cancer, and cervical intraepithelial neoplasia grade III. We found that VSSP adjuvant induced a significant splenomegaly due to accumulation of CD11b(+)Gr-1(+) cells. However, VSSP-derived MDSCs showed a reduced capacity to suppress both allogeneic and Ag-specific CTL response compared with that of tumor-induced MDSCs. Moreover, splenic MDSCs isolated from tumor-bearing mice treated with VSSP were phenotypically more similar to those isolated from VSSP-treated tumor-free mice and much less suppressive than tumor-induced MDSCs, both in vitro and in vivo. Furthermore, different from dendritic cell vaccination, inoculation of VSSP-based vaccine in EG.7-OVA tumor-bearing mice was sufficient to avoid tumor-induced tolerance and stimulate an immune response against OVA Ag, similar to that observed in tumor-free mice. This effect correlated with an accelerated differentiation of MDSCs into mature APCs that was promoted by VSSP. VSSP used as a cancer vaccine adjuvant might thus improve antitumor efficacy not only by stimulating a potent immune response against tumor Ags but also by reducing tumor-induced immunosuppression.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Antineoplásicos/administración & dosificación , Vacunas contra el Cáncer/administración & dosificación , Linfoma/prevención & control , Células Mieloides/inmunología , Nanopartículas/administración & dosificación , Proteolípidos/administración & dosificación , Sarcoma Experimental/prevención & control , Animales , Proteínas de la Membrana Bacteriana Externa/administración & dosificación , Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas contra el Cáncer/inmunología , Línea Celular Tumoral , Femenino , Gangliósido G(M3)/administración & dosificación , Gangliósido G(M3)/inmunología , Inhibidores de Crecimiento/administración & dosificación , Linfoma/inmunología , Linfoma/patología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Transgénicos , Células Mieloides/patología , Neisseria meningitidis/inmunología , Proteolípidos/inmunología , Sarcoma Experimental/inmunología , Sarcoma Experimental/patologíaRESUMEN
Cancers with viral aetiologies can potentially be prevented by antiviral vaccines. Therefore, it is important to understand how viral infections and cancers might be linked. Some cancers frequently carry gammaherpesvirus genomes. However, they generally express the same viral genes as non-transformed cells, and differ mainly in also carrying oncogenic host mutations. Infection, therefore, seems to play a triggering or accessory role in disease. The hit-and-run hypothesis proposes that cumulative host mutations can allow viral genomes to be lost entirely, such that cancers remaining virus-positive represent only a fraction of those to which infection contributes. This would have considerable implications for disease control. However, the hit-and-run hypothesis has so far lacked experimental support. Here, we tested it by using Cre-lox recombination to trigger transforming mutations in virus-infected cells. Thus, 'floxed' oncogene mice were infected with Cre recombinase-positive murid herpesvirus-4 (MuHV-4). The emerging cancers showed the expected genetic changes but, by the time of presentation, almost all lacked viral genomes. Vaccination with a non-persistent MuHV-4 mutant nonetheless conferred complete protection. Equivalent human gammaherpesvirus vaccines could therefore potentially prevent not only viral genome-positive cancers, but possibly also some cancers less suspected of a viral origin because of viral genome loss.
Asunto(s)
Vacunas contra el Cáncer/farmacología , Infecciones por Herpesviridae/inmunología , Infecciones por Herpesviridae/prevención & control , Rhadinovirus/inmunología , Rhadinovirus/patogenicidad , Infecciones Tumorales por Virus/inmunología , Infecciones Tumorales por Virus/prevención & control , Vacunas Virales/farmacología , Animales , Secuencia de Bases , Cartilla de ADN/genética , Genes p53 , Genes ras , Genoma Viral , Infecciones por Herpesviridae/genética , Infecciones por Herpesviridae/virología , Humanos , Ratones , Ratones Mutantes , Ratones Transgénicos , Modelos Biológicos , Mutagénesis Insercional , Mutación , Rhadinovirus/genética , Sarcoma Experimental/genética , Sarcoma Experimental/inmunología , Sarcoma Experimental/prevención & control , Sarcoma Experimental/virología , Infecciones Tumorales por Virus/genética , Infecciones Tumorales por Virus/virología , Vacunación/métodosRESUMEN
Mass spectrometric analysis identified the peptide recognized by a cytotoxic T lymphocyte (CTL) specific for the chemically induced BALB/c Meth A sarcoma as derived from a 17beta-hydroxysteroid dehydrogenase type 12 (Hsd17b12) pseudogene present in the BALB/c genome, but only expressed in Meth A sarcoma. The sequence of the peptide is TYDKIKTGL and corresponds to Hsd17b12(114-122) with threonine instead of isoleucine at codon 114 and is designated Hsd17b12(114T). Immunization of mice with an Hsd17b12(114T) peptide-pulsed dendritic cell-based vaccine or a non-viral plasmid construct expressing the Hsd17b12(114T) peptide protected the mice from lethal Meth A tumor challenge in tumor rejection assays. A Hsd17b12(114-122) peptide-pulsed vaccine was ineffective in inducing resistance in mice to Meth A sarcoma. These results confirm the immunogenicity of the identified tumor peptide, as well as demonstrate the efficacies of these vaccine vehicles. These findings suggest that the role of the human homolog of Hsd17b12, HSD17B12, as a potential human tumor antigen be explored.
Asunto(s)
17-Hidroxiesteroide Deshidrogenasas/genética , Antígenos de Neoplasias/inmunología , Vacunas contra el Cáncer/inmunología , Células Dendríticas/inmunología , Antígenos de Histocompatibilidad/inmunología , Péptidos/inmunología , Seudogenes/inmunología , 17-Hidroxiesteroide Deshidrogenasas/inmunología , Secuencia de Aminoácidos , Animales , Línea Celular Tumoral , Citotoxicidad Inmunológica , Femenino , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/prevención & control , Neoplasias Pulmonares/secundario , Ratones , Ratones Endogámicos BALB C , Péptidos/genética , Péptidos/metabolismo , Sarcoma Experimental/inmunología , Sarcoma Experimental/patología , Sarcoma Experimental/prevención & control , Linfocitos T Citotóxicos/inmunologíaRESUMEN
A large number of active principles from traditional medicinal plants have been reported to have chemopreventive properties. In the present study, therapeutic efficacy of an aqueous extract of Indigofera aspalathoides against growth of transplanted experimental fibrosarcomas in Wistar strain male albino rats was tested. Tumors which appeared about six weeks after implantation were highly localized and were maintained by serial transplantation. Rats were divided into four groups. Group I served as normal control animals. Group II were fibrosarcoma bearing animals. Group III were animals with fibrosarcoma treated with Indigofera aspalathoides aqueous extracts at a dose of 250 mg/kg. b. w. per day for 30 days. Group IV animals were treated with aqueous extract of Indigofera aspalathoides alone. Reduction in tumor weight was noted in Group III as compared to II. The levels of cytochrome C in liver and kidney, the levels of cytochrome P450 and cytochrome b5 in liver microsomes, phase I biotransformation enzymes NADPH-cytochrome P450, NADPH-cytochrome b5, and aniline hydroxylase, and the phase II enzymes glutathione-S-transferase and UDP glucuronyl transferase indicated that their modulation played a role in the therapeutic efficacy of Indigofera aspalathoides against experimental fibrosarcoma.
Asunto(s)
Inactivación Metabólica , Indigofera/química , Fitoterapia , Extractos Vegetales/uso terapéutico , Sarcoma Experimental/prevención & control , Xenobióticos/metabolismo , Anilina Hidroxilasa/metabolismo , Animales , Biotransformación , Sistema Enzimático del Citocromo P-450/metabolismo , Citocromos b5/metabolismo , Glucuronosiltransferasa/metabolismo , Glutatión Transferasa/metabolismo , Masculino , Metilcolantreno , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Ratas , Ratas Wistar , Sarcoma Experimental/inducido químicamente , Sarcoma Experimental/patologíaRESUMEN
3-Methylcholanthrene (MCA)-induced sarcomas have been used as conventional tools for investigating immunosurveillance against tumor development. However, MCA-induced sarcoma is not always an ideal model for the study of the human cancer system because carcinomas and not sarcomas are the dominant types of human cancers. To resolve this problem, we established a novel and simple method to induce mouse squamous cell carcinomas (SCCs). As well known, the subcutaneous injection of MCA caused the formation of sarcomas at 100% incidence. However, we here first succeeded at inducing SCC at 60% of incidence within 2 months by a single intra-dermal injection of MCA. Using this primary SCC model, we demonstrated the critical role of interferon (IFN)-gamma-dependent type 1 immunity in immunosurveillance against SCC from the following results: (i) The incidence of SCC was accelerated in IFN-gamma-deficient mice compared with that in wild-type mice; (ii) In vivo injection of CpG-oligodeoxynucleotides (CpG-ODN) caused a marked reduction in the incidence of SCC in parallel with the activation of type 1-dependent antitumor immunity and (iii) The antitumor activity of CpG-ODN was significantly decreased in IFN-gamma-deficient mice. Thus, our established MCA-induced mouse SCC model could be a powerful tool for evaluating immunosurveillance mechanisms during the development of SCC and might result in a novel strategy to address immunosurveillance mechanisms of human cancer.
Asunto(s)
Carcinoma de Células Escamosas/inmunología , Modelos Animales de Enfermedad , Vigilancia Inmunológica/inmunología , Interferón gamma/fisiología , Sarcoma Experimental/inmunología , Neoplasias Cutáneas/inmunología , Células TH1/inmunología , Animales , Western Blotting , Carcinógenos , Carcinoma de Células Escamosas/inducido químicamente , Carcinoma de Células Escamosas/prevención & control , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Metilcolantreno , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Oligodesoxirribonucleótidos/farmacología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sarcoma Experimental/inducido químicamente , Sarcoma Experimental/prevención & control , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/prevención & control , Tasa de SupervivenciaRESUMEN
OX40 agonists have potent immunotherapeutic effects against a variety of murine tumors, yet it is unclear the role that age-related immune senescence plays on their efficacy. We found that middle-aged and elderly tumor-bearing mice (12 and 20 mo old, respectively) treated with anti-OX40 were less responsive compared with young mice 6 mo or less of age. Decreased tumor-free survival was observed in both male and female mice, and was not due to changes in the surface expression of OX40 on T cells in older animals. Enumeration of cytokine-producing effector T cells in tumor-bearing mice revealed a significant decline in these cells in the older mice treated with anti-OX40 compared with their younger counterparts. The decrease of this critical T cell population in middle-aged mice was not a result of inherent T cell deficiencies, but was revealed to be T cell extrinsic. Finally, combining IL-12, an innate cytokine, with anti-OX40 boosted levels of differentiated effector T cells in the older anti-OX40-treated mice and partially restored the defective antitumor responses in the middle-aged mice. Our data show that the anti-OX40-enhancement of tumor immunity and effector T cell numbers is decreased in middle-aged mice and was partially reversed by coadministration of the proinflammatory cytokine IL-12.
Asunto(s)
Envejecimiento/inmunología , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/patología , Diferenciación Celular/inmunología , Rechazo de Injerto/inmunología , Rechazo de Injerto/patología , Receptores OX40/fisiología , Animales , Anticuerpos/administración & dosificación , Anticuerpos/uso terapéutico , Linfocitos T CD4-Positivos/metabolismo , Línea Celular Tumoral , Neoplasias del Colon/inmunología , Neoplasias del Colon/fisiopatología , Neoplasias del Colon/prevención & control , Femenino , Rechazo de Injerto/metabolismo , Mediadores de Inflamación/administración & dosificación , Interleucina-12/administración & dosificación , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Transgénicos , Receptores OX40/antagonistas & inhibidores , Receptores OX40/inmunología , Sarcoma Experimental/inmunología , Sarcoma Experimental/fisiopatología , Sarcoma Experimental/prevención & controlRESUMEN
The objective of the present study was to isolate a lectin from fresh fruiting bodies of the mushroom Pleurotus citrinopileatus and examine it for various biological activities. The isolation procedure comprised ion exchange chromatography on DEAE-cellulose, CM-celluloses, and Q-Sepharose, and gel filtration on Superdex 75. A homodimeric 32.4 kDa lectin displaying high hemagglutinating activity was isolated with over 110 fold of purification. Its N-terminal amino acid sequence, QYSQMAQVME, has not been reported for other lectins. The lectin was unadsorbed on DEAE-cellulose in 0.001 M NH4HCO3 buffer (pH 9.4), but adsorbed on CM-cellulose in 0.001 M NH4OAc buffer (pH 4.8) and eluted by approximately 0.05 M NaCl in the same buffer. The lectin was subsequently adsorbed on Q-Sepharose and eluted by a linear gradient of 0-0.2 M NaCl in 10 mM NH4HCO3 buffer (pH 8.5). The lectin was obtained in a purified form after gel filtration by fast protein liquid chromatography on Superdex 75. The hemagglutinating activity of the lectin was inhibited by maltose, O-nitrophenyl-beta-d-galactopyranoside, O/P-nitrophenyl-beta-d-glucuronide and insulin. It was stable at temperatures up to 60 degrees C, and in NaOH and HCl solutions up to 0.1 M and 0.006 M concentration, respectively. It was sensitive to inhibition by HgCl2 and potentiation by AlCl3. The lectin exerted potent antitumor activity in mice bearing sarcoma 180, and caused approximately 80% inhibition of tumor growth when administered intraperitonealy at 5 mg/kg daily for 20 days. It elicited a mitogenic response from murine splenocytes in vitro with the maximal response at a lectin concentration of 2 microM. The lectin inhibited HIV-1 reverse transcriptase with an IC50 of 0.93 microM. It was devoid of antifungal activity.
Asunto(s)
Agaricales/química , Antineoplásicos/farmacología , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Lectinas/farmacología , Inhibidores de la Transcriptasa Inversa/farmacología , Sarcoma Experimental/prevención & control , Secuencia de Aminoácidos , Animales , Antineoplásicos/química , Antineoplásicos/aislamiento & purificación , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cromatografía en Gel , Cromatografía por Intercambio Iónico , Electroforesis en Gel de Poliacrilamida , Cuerpos Fructíferos de los Hongos/química , Pruebas de Hemaglutinación , Lectinas/química , Lectinas/aislamiento & purificación , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , Datos de Secuencia Molecular , Peso Molecular , Inhibidores de la Transcriptasa Inversa/química , Inhibidores de la Transcriptasa Inversa/aislamiento & purificación , Sarcoma Experimental/patología , Bazo/citología , Bazo/efectos de los fármacosRESUMEN
Homeopathy is considered as one modality for cancer therapy. However, there are only very few clinical reports on the activity of the drugs, as well as in experimental animals. Presently we have evaluated the inhibitory effects of potentized homeopathic preparations against N'-nitrosodiethylamine (NDEA) induced hepatocellular carcinoma in rats as well as 3-methylcholanthrene-induced sarcomas in mice. We have used Ruta, Hydrastis, Lycopodium and Thuja, which are commonly employed in homeopathy for treating cancer. Administration of NDEA in rats resulted in tumor induction in the liver and elevated marker enzymes such as gamma-glutamyl transpeptidase, glutamate pyruvate transaminase, glutamate oxaloacetate transaminase and alkaline phosphatase in the serum and in liver. Concomitant administration of homeopathic drugs retarded the tumor growth and significantly reduced the elevated marker enzymes level as revealed by morphological, biochemical and histopathological evaluation. Out of the four drugs studied, Ruta 200c showed maximum inhibition of liver tumor development. Ruta 200c and phosphorus 1M were found to reduce the incidence of 3-methylcholanthrene-induced sarcomas and also increase the life span of mice harboring the tumours. These studies demonstrate that homeopathic drugs, at ultra low doses, may be able to decrease tumor induction by carcinogen administration. At present we do not know the mechanisms of action of these drugs useful against carcinogenesis.
Asunto(s)
Drogas en Investigación/uso terapéutico , Homeopatía , Neoplasias Hepáticas Experimentales/prevención & control , Hígado/efectos de los fármacos , Sarcoma Experimental/prevención & control , Animales , Femenino , Hígado/patología , Neoplasias Hepáticas Experimentales/inducido químicamente , Metilcolantreno/toxicidad , Ratas , Ratas Wistar , Ruta/química , Sarcoma Experimental/inducido químicamenteRESUMEN
Although intraocular tumors reside in an immune-privileged environment, T cells can circumvent immune privilege and mediate tumor rejection without inducing damage to normal ocular tissue. In this study, we used a well-characterized tumor, Ad5E1 (adenovirus type 5 early region 1), to analyze the role of CD8+ T cells in the pristine rejection of intraocular tumors. It has been previously documented that Ad5E1 tumor rejection can occur in the absence of CD8+ T cells. However, here we find that CD8+ T cells infiltrated intraocular Ad5E1 tumors in C57BL/6 mice. Surprisingly, CD8+ T cells from tumor-rejector mice could mediate intraocular tumor rejection following adoptive transfer to SCID mice. In determining the mechanisms behind CD8+ T cell-mediated tumor rejection, we discovered that antitumor CTL activity was neither observed nor necessary for rejection of the intraocular tumors. CD8+ T cells from rejector mice did not produce IFN-gamma in response to Ad5E1 tumor Ags or use FasL to mediate intraocular tumor rejection. Also, CD8+ T cells did not use perforin or TRAIL, as CD8+ T cells from perforin knockout (KO) and TRAIL KO mice conferred protection to SCID recipient mice following adoptive transfer. We discovered that CD8+ T cells used TNF-alpha to mediate tumor rejection, because Ad5E1 tumor cells were highly sensitive to TNF-alpha-induced apoptosis and CD8+ T cells from TNF-alpha KO mice did not protect SCID mice from progressive Ad5E1 tumor growth. The results indicate that CD8+ T cells circumvent immune privilege and mediate intraocular tumor rejection by a TNF-alpha-dependent manner while leaving the eye intact and vision preserved.
Asunto(s)
Cámara Anterior/inmunología , Cámara Anterior/virología , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/metabolismo , Neoplasias del Ojo/inmunología , Neoplasias del Ojo/prevención & control , Rechazo de Injerto/inmunología , Factor de Necrosis Tumoral alfa/fisiología , Adenovirus Humanos/inmunología , Animales , Cámara Anterior/patología , Linfocitos T CD8-positivos/patología , Línea Celular Tumoral , Movimiento Celular/inmunología , Neoplasias del Ojo/patología , Neoplasias del Ojo/virología , Rechazo de Injerto/genética , Rechazo de Injerto/patología , Rechazo de Injerto/virología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos DBA , Ratones Noqueados , Ratones SCID , Trasplante de Neoplasias/inmunología , Sarcoma Experimental/inmunología , Sarcoma Experimental/patología , Sarcoma Experimental/prevención & control , Factor de Necrosis Tumoral alfa/deficiencia , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
We previously observed that rhinacanthins-C, -N and -Q, three main naphthoquinone esters isolated from the roots of Thai medicinal plant; Rhinacanthus nasutus KURZ. (Acanthaceae) induced apoptosis of human cervical carcinoma HeLaS3 cells. Since these rhinacanthins showed limited solubility in aqueous medium, we attempted to entrap them into liposomal membrane: Liposomalization enabled injection of the drugs and the drugs were expected to transfer to lipoproteins in the bloodstream. Liposomal formulations of rhinacanthins-C, -N and -Q showed strong antiproliferative activity against HeLaS3 cells with the IC50 values of 32, 17, 70 microM; 19, 17, 52 microM and 2.7, 2.0 and 5.0 microM for the exposure time of 24, 48, and 72 h, respectively. These liposomes suppressed the tumor growth in Meth-A sarcoma-bearing BALB/c mice at the dose of 5.0 mg/kg/d for 10 d. Among rhinacanthins, liposomal rhinacanthin-N significantly suppressed solid tumor growth. Based on these results, our findings demonstrated that rhinacanthin-N suppressed tumor growth in vivo, and suggested that liposomes are useful for preparing injectable formulation of hydrophobic drugs.
Asunto(s)
Acanthaceae/química , Antineoplásicos Fitogénicos/farmacología , Naftoquinonas/farmacología , Plantas Medicinales/química , Animales , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Ascitis/patología , Ascitis/prevención & control , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ésteres , Células HeLa , Humanos , Lignanos/química , Lignanos/aislamiento & purificación , Lignanos/farmacología , Liposomas , Masculino , Ratones , Ratones Endogámicos BALB C , Estructura Molecular , Naftoquinonas/química , Naftoquinonas/aislamiento & purificación , Trasplante de Neoplasias/métodos , Fitoterapia/métodos , Extractos Vegetales/química , Extractos Vegetales/farmacología , Raíces de Plantas/química , Sarcoma Experimental/patología , Sarcoma Experimental/prevención & control , Análisis de Supervivencia , TailandiaRESUMEN
The evidence has been produced that immunological mechanisms are involved in the known anticancer phenomenon of T. cruzi. Non-inbred albino mice were immunized with avirulent cultures of three strains and seven clones and then transplanted a tumor--sarcoma-180 or Ehrlich's adenocarcinoma. The used cultures induced the generation of T. cruzi antibodies whose level peaked by postimmunization days 50-60: the titers being 1:40-1:80 and the spread among the mice being 60%. Concurrently, immunization against T. cruzi provided a certain oncoprotective effect. In the immunized mice, the sizes of sarcoma-180 and adenocarcinoma were 1.5-2.0 and 2.0-2.5 times, respectively, less than those in the non-immunized ones. The antitumor protection was directly related to the murine blood T. cruzi antibody level during which implantation of a tumor occurred. At the peak of an immune response, the effect was 2 times higher than that in the early postimmunization periods. T. cruzi strains that were more immunogenic than clones ensured a more significant oncoprotection. The latter was more considerable in mice having antibody titers of 1:40-1:80 than in those with antibody titers of 1:10-1:20 and particularly in the animals showing no humoral response to the administration of the parasites at all.
Asunto(s)
Adenocarcinoma/prevención & control , Enfermedad de Chagas/inmunología , Inmunización , Vacunas Antiprotozoos/administración & dosificación , Sarcoma Experimental/prevención & control , Neoplasias Cutáneas/prevención & control , Trypanosoma cruzi/inmunología , Animales , Anticuerpos Antiprotozoarios/sangre , Inyecciones Intramusculares , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Ratones , Especificidad de la Especie , Factores de Tiempo , Vacunas Atenuadas/administración & dosificaciónRESUMEN
Immunization with serological identification of Ags by recombinant expression cloning (SEREX)-defined self-Ags leads to generation/activation of CD4+ CD25+ regulatory T cells with suppressive activities and enhanced expression of Foxp3. This is associated with increased susceptibility to pulmonary metastasis following challenge with syngeneic tumor cells and enhanced development of 3-methylcholanthrene-induced primary tumors. In contrast, coimmunization with the same SEREX-defined self-Ags mixed with a CTL epitope results in augmented CTL activity and heightened resistance to pulmonary metastasis, both of which depend on CD4+ Th cells. These active regulatory T cells and Th cells were derived from two distinct CD4+ T cell subsets, CD4+ CD25+ T cells and CD4+ CD25- T cells, respectively. In the present study, IFN-gamma was found to abrogate the generation/activation of CD4+ CD25+ regulatory T cells by immunization with SEREX-defined self-Ag. CD4+ CD25+ T cells from these IFN-gamma-treated mice failed to exhibit immunosuppressive activity as measured by 1) increased number of pulmonary metastasis, 2) enhanced development of 3-methylcholanthrene-induced primary tumors, 3) suppression of peptide-specific T cell proliferation, and 4) enhanced expression of Foxp3. The important role of IFN-gamma produced by CD8+ T cells was shown in experiments demonstrating that CD4+ CD25+ T cells cotransferred with CD8+ T cells from IFN-gamma(-/-) mice, but not from wild-type BALB/c mice, became immunosuppressive and enhanced pulmonary metastasis when recipient animals were subsequently immunized with a SEREX-defined self-Ag and a CTL epitope. These findings support the idea that IFN-gamma regulates the generation/activation of CD4+ CD25+ regulatory T cells.
Asunto(s)
Interferón gamma/fisiología , Receptores de Interleucina-2/biosíntesis , Sarcoma Experimental/inmunología , Sarcoma Experimental/prevención & control , Linfocitos T Reguladores/inmunología , Animales , Línea Celular Tumoral , Células Cultivadas , Epítopos/inmunología , Femenino , Proteínas de Choque Térmico/inmunología , Interferón gamma/deficiencia , Interferón gamma/genética , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/prevención & control , Neoplasias Pulmonares/secundario , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Ratones SCID , Ratones Transgénicos , Receptores de Interleucina-2/metabolismo , Sarcoma Experimental/patología , Subgrupos de Linfocitos T/inmunología , Linfocitos T Citotóxicos/inmunologíaRESUMEN
The C5a anaphylatoxin protein plays a central role in inflammation associated with complement activation. This protein is commonly regarded as one of the most potent inducers of the inflammatory response and a C5a peptide agonist was used as a molecular adjuvant. However, the full length C5a protein has not been tested as a potential tumor therapy. In this report, we describe the creation of a mini-gene construct that directs C5a expression to any cell of interest. Functional expression could be demonstrated in the murine mammary sarcoma, EMT6. When C5a expressing cells were injected into syngeneic mice, most C5a-expressing clones had significantly reduced tumor growth. Further characterization of a clone expressing low levels of C5a demonstrated that one-third of mice injected with this line had complete tumor regression. The mice whose tumors regressed were immune to subsequent challenge with unmodified EMT6 cells, suggesting that a component of the innate immune response can be used to augment adaptive immunity. Cellular analyses demonstrated that a significant difference in actual tumor cell number could be detected as early as day 10. A block in cell cycle progression was evident at all time points and high levels of apoptosis were observed early in the regression event. These data demonstrate that the complement protein C5a can play a significant protective role in tumor immunity.